Terns Pharmaceuticals, Inc. (NASDAQ:TERN) Given Average Recommendation of “Buy” by Analysts

Shares of Terns Pharmaceuticals, Inc. (NASDAQ:TERN) have been given a consensus recommendation of “Buy” by the fourteen analysts that are covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, eleven have assigned a buy recommendation and two have assigned a strong buy recommendation to the company. The average 12-month target price among brokers that have updated their coverage on the stock in the last year is $58.1111.

Several research firms have recently commented on TERN. Citizens Jmp boosted their price objective on Terns Pharmaceuticals from $35.00 to $57.00 and gave the company a “market outperform” rating in a report on Thursday, December 11th. Jefferies Financial Group reissued a “buy” rating and issued a $70.00 price target on shares of Terns Pharmaceuticals in a research report on Wednesday, December 10th. Truist Financial boosted their price target on shares of Terns Pharmaceuticals from $35.00 to $56.00 and gave the company a “buy” rating in a research note on Tuesday, December 9th. Mizuho upped their price objective on shares of Terns Pharmaceuticals from $33.00 to $54.00 and gave the stock an “outperform” rating in a report on Tuesday, December 9th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Terns Pharmaceuticals in a research note on Monday, December 29th.

Insider Transactions at Terns Pharmaceuticals

In related news, insider Emil Kuriakose sold 1,155 shares of the company’s stock in a transaction dated Friday, January 2nd. The shares were sold at an average price of $38.57, for a total value of $44,548.35. Following the sale, the insider owned 50,365 shares in the company, valued at $1,942,578.05. This represents a 2.24% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CEO Amy L. Burroughs sold 14,583 shares of Terns Pharmaceuticals stock in a transaction dated Monday, March 16th. The shares were sold at an average price of $46.71, for a total value of $681,171.93. Following the transaction, the chief executive officer owned 288,976 shares of the company’s stock, valued at $13,498,068.96. This trade represents a 4.80% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 170,409 shares of company stock worth $6,563,769 in the last 90 days. 1.50% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the stock. Commodore Capital LP purchased a new stake in Terns Pharmaceuticals in the 3rd quarter valued at $42,807,000. Vestal Point Capital LP purchased a new position in Terns Pharmaceuticals during the 4th quarter worth $181,800,000. Avoro Capital Advisors LLC purchased a new position in Terns Pharmaceuticals during the 4th quarter worth $175,740,000. Janus Henderson Group PLC bought a new stake in shares of Terns Pharmaceuticals in the 4th quarter worth $136,496,000. Finally, Capitolis Liquid Global Markets LLC bought a new stake in shares of Terns Pharmaceuticals in the 4th quarter worth $123,026,000. Hedge funds and other institutional investors own 98.26% of the company’s stock.

Terns Pharmaceuticals Stock Performance

TERN stock opened at $48.44 on Monday. The stock’s 50 day simple moving average is $39.70 and its 200 day simple moving average is $27.52. The company has a market cap of $5.03 billion, a P/E ratio of -47.03 and a beta of -0.31. Terns Pharmaceuticals has a fifty-two week low of $1.87 and a fifty-two week high of $50.00.

Terns Pharmaceuticals Company Profile

Terns Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing oral small‐molecule therapies for the treatment of chronic liver diseases and other serious conditions. The company’s research and development efforts center on novel mechanisms of action designed to address the underlying causes of progressive liver disorders, including inflammation, fibrosis and metabolic dysregulation. By advancing targeted compounds that can be administered orally, Terns aims to offer patients more convenient and effective treatment options compared to injectable or biologic therapies.

The company’s pipeline features several candidates in various stages of preclinical and clinical evaluation.